25 XP   0   0   10

Aprogen Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse En together

PenkeI guess you are interested in Aprogen Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aprogen Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Aprogen Pharmaceuticals Inc

I send you an email if I find something interesting about Aprogen Pharmaceuticals Inc.

Quick analysis of En (30 sec.)










What can you expect buying and holding a share of En? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩560.72
Expected worth in 1 year
₩345.19
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
₩-215.53
Return On Investment
-113.4%

For what price can you sell your share?

Current Price per Share
₩190.00
Expected price per share
₩156.00 - ₩308.00
How sure are you?
50%

1. Valuation of En (5 min.)




Live pricePrice per Share (EOD)

₩190.00

Intrinsic Value Per Share

₩-1,432.22 - ₩-1,715.56

Total Value Per Share

₩-871.50 - ₩-1,154.84

2. Growth of En (5 min.)




Is En growing?

Current yearPrevious yearGrowGrow %
How rich?$258m$405m-$61.9m-18.1%

How much money is En making?

Current yearPrevious yearGrowGrow %
Making money-$20.6m$1.3m-$22m-106.6%
Net Profit Margin-127.4%12.5%--

How much money comes from the company's main activities?

3. Financial Health of En (5 min.)




What can you expect buying and holding a share of En? (5 min.)

Welcome investor! En's management wants to use your money to grow the business. In return you get a share of En.

What can you expect buying and holding a share of En?

First you should know what it really means to hold a share of En. And how you can make/lose money.

Speculation

The Price per Share of En is ₩190.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of En.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in En, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩560.72. Based on the TTM, the Book Value Change Per Share is ₩-53.88 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-32.99 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of En.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.10-0.1%-0.030.0%0.000.0%-0.010.0%0.000.0%
Usd Book Value Change Per Share-0.18-0.1%-0.040.0%-0.020.0%0.010.0%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.18-0.1%-0.040.0%-0.020.0%0.010.0%0.010.0%
Usd Price Per Share0.20-0.25-0.42-0.72-1.53-
Price to Earnings Ratio-0.49-9.45-16.13-16.36-60.04-
Price-to-Total Gains Ratio-1.10-606.70-172.96-153.44--115.39-
Price to Book Ratio0.52-0.48-0.68-2.05-14.42-
Price-to-Total Gains Ratio-1.10-606.70-172.96-153.44--115.39-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.133
Number of shares7518
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.040.01
Usd Total Gains Per Share-0.040.01
Gains per Quarter (7518 shares)-283.5787.31
Gains per Year (7518 shares)-1,134.26349.25
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1134-11440349339
20-2269-22780698688
30-3403-3412010481037
40-4537-4546013971386
50-5671-5680017461735
60-6806-6814020952084
70-7940-7948024452433
80-9074-9082027942782
90-10208-10216031433131
100-11343-11350034923480

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%8.04.00.066.7%12.08.00.060.0%17.015.08.042.5%17.015.012.038.6%
Book Value Change Per Share2.02.00.050.0%7.05.00.058.3%12.08.00.060.0%24.016.00.060.0%26.018.00.059.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.044.00.0%
Total Gains per Share2.02.00.050.0%7.05.00.058.3%12.08.00.060.0%24.016.00.060.0%26.018.00.059.1%

Fundamentals of En

About Aprogen Pharmaceuticals Inc

Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. It offers approximately 200 types of medicines, including ethical and over the counter drugs. The company offers its drugs for transfusion, digestive system, osteoarthritis, skeletal muscle relaxants, NSAIDs, osteoporosis, circulatory system, endocrine, respiratory system, urinary system, depilatory, antihistamines and antiallergics, obesity, brain function, neurologics, and male pattern hair loss. It also provides anti-biotic, anti-fungal, anti-viral, anti-ulcerant, anti-epliepsy products; external agents; anti-cancer drugs; amino-acid nutrient transfusion agents; and cosmetics. Aprogen Biologics Inc. was founded in 1960 and is headquartered in Seongnam-si, South Korea.

Fundamental data was last updated by Penke on 2024-03-24 06:12:07.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Aprogen Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit En earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare En to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -426.4% means that ₩-4.26 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aprogen Pharmaceuticals Inc:

  • The MRQ is -426.4%. The company is making a huge loss. -2
  • The TTM is -127.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-426.4%TTM-127.4%-299.0%
TTM-127.4%YOY12.5%-139.9%
TTM-127.4%5Y-19.4%-108.0%
5Y-19.4%10Y-13.3%-6.1%
1.1.2. Return on Assets

Shows how efficient En is using its assets to generate profit.

  • Above 5% is considered healthy but always compare En to the Drug Manufacturers - Specialty & Generic industry mean.
  • -16.4% Return on Assets means that En generated ₩-0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aprogen Pharmaceuticals Inc:

  • The MRQ is -16.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.4%TTM-4.9%-11.6%
TTM-4.9%YOY0.3%-5.2%
TTM-4.9%5Y-0.9%-4.0%
5Y-0.9%10Y-0.7%-0.2%
1.1.3. Return on Equity

Shows how efficient En is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare En to the Drug Manufacturers - Specialty & Generic industry mean.
  • -26.3% Return on Equity means En generated ₩-0.26 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aprogen Pharmaceuticals Inc:

  • The MRQ is -26.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-26.3%TTM-7.7%-18.6%
TTM-7.7%YOY0.4%-8.0%
TTM-7.7%5Y-1.4%-6.3%
5Y-1.4%10Y-1.3%-0.1%

1.2. Operating Efficiency of Aprogen Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient En is operating .

  • Measures how much profit En makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare En to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aprogen Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-4.4%+4.4%
TTM-5Y-0.7%+0.7%
5Y-0.7%10Y-1.9%+1.2%
1.2.2. Operating Ratio

Measures how efficient En is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 3.42 means that the operating costs are ₩3.42 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Aprogen Pharmaceuticals Inc:

  • The MRQ is 3.421. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.626. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.421TTM2.626+0.795
TTM2.626YOY1.667+0.960
TTM2.6265Y1.833+0.793
5Y1.83310Y1.452+0.381

1.3. Liquidity of Aprogen Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if En is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.54 means the company has ₩0.54 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Aprogen Pharmaceuticals Inc:

  • The MRQ is 0.537. The company is unable to pay all its short-term debts. -2
  • The TTM is 1.500. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ0.537TTM1.500-0.962
TTM1.500YOY24.071-22.571
TTM1.5005Y20.651-19.151
5Y20.65110Y10.690+9.961
1.3.2. Quick Ratio

Measures if En is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare En to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.09 means the company can pay off ₩0.09 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aprogen Pharmaceuticals Inc:

  • The MRQ is 0.094. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.501. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.094TTM0.501-0.407
TTM0.501YOY20.502-20.001
TTM0.5015Y18.524-18.024
5Y18.52410Y9.708+8.817

1.4. Solvency of Aprogen Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of En assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare En to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.37 means that En assets are financed with 37.4% credit (debt) and the remaining percentage (100% - 37.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aprogen Pharmaceuticals Inc:

  • The MRQ is 0.374. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.281. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.374TTM0.281+0.094
TTM0.281YOY0.088+0.192
TTM0.2815Y0.120+0.161
5Y0.12010Y0.231-0.111
1.4.2. Debt to Equity Ratio

Measures if En is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare En to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 59.9% means that company has ₩0.60 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aprogen Pharmaceuticals Inc:

  • The MRQ is 0.599. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.440. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.599TTM0.440+0.159
TTM0.440YOY0.132+0.308
TTM0.4405Y0.177+0.262
5Y0.17710Y0.365-0.187

2. Market Valuation of Aprogen Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings En generates.

  • Above 15 is considered overpriced but always compare En to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -0.49 means the investor is paying ₩-0.49 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aprogen Pharmaceuticals Inc:

  • The EOD is -0.323. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.492. Based on the earnings, the company is expensive. -2
  • The TTM is 9.446. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD-0.323MRQ-0.492+0.170
MRQ-0.492TTM9.446-9.938
TTM9.446YOY16.133-6.687
TTM9.4465Y16.360-6.914
5Y16.36010Y60.041-43.681
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aprogen Pharmaceuticals Inc:

  • The EOD is -2.291. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.496. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.813. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.291MRQ-3.496+1.206
MRQ-3.496TTM-3.813+0.317
TTM-3.813YOY328.159-331.972
TTM-3.8135Y-3.322-0.491
5Y-3.32210Y196.075-199.398
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of En is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.52 means the investor is paying ₩0.52 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Aprogen Pharmaceuticals Inc:

  • The EOD is 0.339. Based on the equity, the company is cheap. +2
  • The MRQ is 0.517. Based on the equity, the company is cheap. +2
  • The TTM is 0.477. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.339MRQ0.517-0.178
MRQ0.517TTM0.477+0.040
TTM0.477YOY0.680-0.203
TTM0.4775Y2.048-1.571
5Y2.04810Y14.423-12.375
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Aprogen Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---262.708-53.883-79%-32.991-87%16.591-1683%11.868-2314%
Book Value Per Share--560.721745.246-25%879.920-36%726.598-23%426.225+32%
Current Ratio--0.5371.500-64%24.071-98%20.651-97%10.690-95%
Debt To Asset Ratio--0.3740.281+33%0.088+324%0.120+212%0.231+62%
Debt To Equity Ratio--0.5990.440+36%0.132+353%0.177+237%0.365+64%
Dividend Per Share----0%-0%-0%-0%
Eps---147.218-44.967-69%2.980-5041%-7.558-95%-4.454-97%
Free Cash Flow Per Share---20.736-23.591+14%9.195-326%-3.085-85%-2.667-87%
Free Cash Flow To Equity Per Share---20.736-23.591+14%11.770-276%20.227-203%22.600-192%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.800+25%
Intrinsic Value_10Y_max---1715.559--------
Intrinsic Value_10Y_min---1432.222--------
Intrinsic Value_1Y_max---44.688--------
Intrinsic Value_1Y_min---43.820--------
Intrinsic Value_3Y_max---231.228--------
Intrinsic Value_3Y_min---218.792--------
Intrinsic Value_5Y_max---534.664--------
Intrinsic Value_5Y_min---487.916--------
Market Cap124930891520.000-53%190683992320.000231944063072.000-18%394025456544.000-52%675495281163.367-72%1436520645718.021-87%
Net Profit Margin---4.264-1.274-70%0.125-3508%-0.194-95%-0.133-97%
Operating Margin----0%-0.0440%-0.0070%-0.0190%
Operating Ratio--3.4212.626+30%1.667+105%1.833+87%1.452+136%
Pb Ratio0.339-53%0.5170.477+8%0.680-24%2.048-75%14.423-96%
Pe Ratio-0.323+34%-0.4929.446-105%16.133-103%16.360-103%60.041-101%
Price Per Share190.000-53%290.000352.750-18%599.250-52%1027.321-72%2184.719-87%
Price To Free Cash Flow Ratio-2.291+34%-3.496-3.813+9%328.159-101%-3.322-5%196.075-102%
Price To Total Gains Ratio-0.723+34%-1.104606.701-100%172.958-101%153.435-101%-115.388+10353%
Quick Ratio--0.0940.501-81%20.502-100%18.524-99%9.708-99%
Return On Assets---0.164-0.049-70%0.003-5175%-0.009-95%-0.007-96%
Return On Equity---0.263-0.077-71%0.004-7457%-0.014-95%-0.013-95%
Total Gains Per Share---262.708-53.883-79%-32.991-87%16.591-1683%11.868-2314%
Usd Book Value--258084034.418343015421.413-25%405002325.168-36%334432351.994-23%196179421.002+32%
Usd Book Value Change Per Share---0.184-0.038-79%-0.023-87%0.012-1683%0.008-2314%
Usd Book Value Per Share--0.3930.522-25%0.616-36%0.509-23%0.298+32%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.103-0.031-69%0.002-5041%-0.005-95%-0.003-97%
Usd Free Cash Flow---9544378.214-10858180.958+14%4232023.168-326%-1420057.569-85%-1043313.132-89%
Usd Free Cash Flow Per Share---0.015-0.017+14%0.006-326%-0.002-85%-0.002-87%
Usd Free Cash Flow To Equity Per Share---0.015-0.017+14%0.008-276%0.014-203%0.016-192%
Usd Market Cap87451624.064-53%133478794.624162360844.150-18%275817819.581-52%472846696.814-72%1005564452.003-87%
Usd Price Per Share0.133-53%0.2030.247-18%0.419-52%0.719-72%1.529-87%
Usd Profit---67760199.577-20697201.089-69%1371504.234-5041%-3478711.795-95%-2050269.382-97%
Usd Revenue--15892433.85115288634.848+4%11408312.881+39%10964081.989+45%9140159.294+74%
Usd Total Gains Per Share---0.184-0.038-79%-0.023-87%0.012-1683%0.008-2314%
 EOD+3 -5MRQTTM+8 -24YOY+5 -275Y+5 -2710Y+10 -23

3.2. Fundamental Score

Let's check the fundamental score of Aprogen Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.323
Price to Book Ratio (EOD)Between0-10.339
Net Profit Margin (MRQ)Greater than0-4.264
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.094
Current Ratio (MRQ)Greater than10.537
Debt to Asset Ratio (MRQ)Less than10.374
Debt to Equity Ratio (MRQ)Less than10.599
Return on Equity (MRQ)Greater than0.15-0.263
Return on Assets (MRQ)Greater than0.05-0.164
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Aprogen Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.615
Ma 20Greater thanMa 50183.050
Ma 50Greater thanMa 100188.380
Ma 100Greater thanMa 200245.680
OpenGreater thanClose194.000
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Working Capital  79,502,071-10,404,44469,097,62780,358,709149,456,336-114,290,67435,165,662-108,246,745-73,081,082



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets589,396,665
Total Liabilities220,705,187
Total Stockholder Equity368,691,478
 As reported
Total Liabilities 220,705,187
Total Stockholder Equity+ 368,691,478
Total Assets = 589,396,665

Assets

Total Assets589,396,665
Total Current Assets84,857,286
Long-term Assets504,539,379
Total Current Assets
Cash And Cash Equivalents 10,053,360
Net Receivables 14,807,328
Inventory 48,128,195
Other Current Assets 36,135
Total Current Assets  (as reported)84,857,286
Total Current Assets  (calculated)73,025,018
+/- 11,832,268
Long-term Assets
Property Plant Equipment 318,211,931
Intangible Assets 6,240,853
Long-term Assets Other 27,983
Long-term Assets  (as reported)504,539,379
Long-term Assets  (calculated)324,480,767
+/- 180,058,612

Liabilities & Shareholders' Equity

Total Current Liabilities157,938,368
Long-term Liabilities62,766,819
Total Stockholder Equity368,691,478
Total Current Liabilities
Short Long Term Debt 129,360,289
Accounts payable 1,333,066
Other Current Liabilities 0
Total Current Liabilities  (as reported)157,938,368
Total Current Liabilities  (calculated)130,693,355
+/- 27,245,013
Long-term Liabilities
Long term Debt 32,000,000
Capital Lease Obligations Min Short Term Debt19,637,004
Long-term Liabilities Other -1
Long-term Liabilities  (as reported)62,766,819
Long-term Liabilities  (calculated)51,637,003
+/- 11,129,816
Total Stockholder Equity
Total Stockholder Equity (as reported)368,691,478
Total Stockholder Equity (calculated)0
+/- 368,691,478
Other
Capital Stock332,877,345
Common Stock Shares Outstanding 657,531
Net Debt 151,306,929
Net Invested Capital 530,051,767
Net Working Capital -73,081,082
Property Plant and Equipment Gross 410,365,058



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
83,171,049
77,254,011
76,463,969
78,259,220
87,326,360
82,765,427
86,515,139
84,828,018
86,281,673
84,170,565
84,378,010
85,221,295
105,051,933
128,744,491
128,194,570
128,690,599
130,743,791
125,237,781
168,633,236
158,272,087
156,696,681
217,682,523
219,749,215
217,062,048
196,845,934
199,114,599
379,274,701
365,282,978
376,443,781
373,428,606
617,308,502
615,309,134
611,983,073
612,585,869
611,144,807
614,621,103
617,763,354
618,346,282
629,750,702
684,140,417
682,584,555
694,623,189
744,896,070
589,396,665
589,396,665744,896,070694,623,189682,584,555684,140,417629,750,702618,346,282617,763,354614,621,103611,144,807612,585,869611,983,073615,309,134617,308,502373,428,606376,443,781365,282,978379,274,701199,114,599196,845,934217,062,048219,749,215217,682,523156,696,681158,272,087168,633,236125,237,781130,743,791128,690,599128,194,570128,744,491105,051,93385,221,29584,378,01084,170,56586,281,67384,828,01886,515,13982,765,42787,326,36078,259,22076,463,96977,254,01183,171,049
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
83,068,680
57,398,731
62,127,270
76,758,131
66,007,717
65,274,803
88,456,971
87,181,437
87,286,944
71,803,660
72,461,005
199,726,783
195,591,101
211,555,686
220,542,106
458,191,011
336,522,784
333,895,534
336,419,387
349,106,700
353,474,278
357,659,236
360,984,536
392,352,449
240,608,129
228,935,248
234,185,474
167,987,621
84,857,286
84,857,286167,987,621234,185,474228,935,248240,608,129392,352,449360,984,536357,659,236353,474,278349,106,700336,419,387333,895,534336,522,784458,191,011220,542,106211,555,686195,591,101199,726,78372,461,00571,803,66087,286,94487,181,43788,456,97165,274,80366,007,71776,758,13162,127,27057,398,73183,068,680000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,216,124
19,528,290
16,758,157
29,165,250
23,784,457
14,249,973
31,281,551
31,341,853
21,630,495
5,315,905
5,580,521
37,729,414
30,296,955
41,651,387
75,403,489
80,825,198
64,795,655
40,394,981
64,356,602
49,147,655
35,074,090
16,870,220
73,992,970
14,212,943
23,608,843
14,478,586
19,971,954
11,106,546
10,053,360
10,053,36011,106,54619,971,95414,478,58623,608,84314,212,94373,992,97016,870,22035,074,09049,147,65564,356,60240,394,98164,795,65580,825,19875,403,48941,651,38730,296,95537,729,4145,580,5215,315,90521,630,49531,341,85331,281,55114,249,97323,784,45729,165,25016,758,15719,528,29026,216,124000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
54,001
72,000
30,000
60,000
90,000
4,120,000
10,000,000
10,000,000
0
41,191,171
40,597,604
135,564,696
139,212,967
142,061,113
116,588,343
346,014,718
140,279,119
130,002,080
85,002,250
100,001,895
89,861,208
74,899,167
1,710
74,874,079
75,464,774
75,939,675
76,173,671
390,000
0
0390,00076,173,67175,939,67575,464,77474,874,0791,71074,899,16789,861,208100,001,89585,002,250130,002,080140,279,119346,014,718116,588,343142,061,113139,212,967135,564,69640,597,60441,191,171010,000,00010,000,0004,120,00090,00060,00030,00072,00054,001000000000000000
       Net Receivables 
22,625,154
20,556,764
19,128,656
13,242,426
12,885,010
13,490,662
13,694,983
13,214,562
13,293,453
13,336,815
13,496,534
14,964,124
15,294,589
16,248,871
15,693,045
16,111,742
16,567,171
16,525,705
18,134,420
23,369,537
17,340,296
21,216,522
19,528,127
39,875,520
14,876,745
15,317,214
13,505,157
93,075,004
106,373,212
114,618,175
205,002,853
119,490,406
149,971,078
175,778,267
188,114,205
215,754,833
253,524,788
274,446,727
289,968,400
17,769,324
15,699,871
24,719,389
18,870,574
14,807,328
14,807,32818,870,57424,719,38915,699,87117,769,324289,968,400274,446,727253,524,788215,754,833188,114,205175,778,267149,971,078119,490,406205,002,853114,618,175106,373,21293,075,00413,505,15715,317,21414,876,74539,875,52019,528,12721,216,52217,340,29623,369,53718,134,42016,525,70516,567,17116,111,74215,693,04516,248,87115,294,58914,964,12413,496,53413,336,81513,293,45313,214,56213,694,98313,490,66212,885,01013,242,42619,128,65620,556,76422,625,154
       Other Current Assets 
463,357
429,438
424,973
2,420,020
1,575,257
1,387,496
1,382,344
1,652,501
579,139
582,860
471,449
504,254
708,503
705,758
526,599
516,392
607,265
527,160
597,094
404,579
812,419
449,741
515,250
349,252
17,397
16,729
182,743
1,128,127
1,279,684
594,320
1,329,986
1,903,955
2,184,595
1,113,979
1,977,086
2,353,880
2,682,825
1,865,232
3,010,551
26,283
1,679,153
1,330,333
3,093,530
36,135
36,1353,093,5301,330,3331,679,15326,2833,010,5511,865,2322,682,8252,353,8801,977,0861,113,9792,184,5951,903,9551,329,986594,3201,279,6841,128,127182,74316,72917,397349,252515,250449,741812,419404,579597,094527,160607,265516,392526,599705,758708,503504,254471,449582,860579,1391,652,5011,382,3441,387,4961,575,2572,420,020424,973429,438463,357
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
125,042,274
126,653,593
179,547,918
151,736,877
146,933,095
152,886,500
159,117,490
278,786,350
278,087,539
276,166,482
262,038,107
261,146,825
260,104,118
257,361,746
237,398,253
443,532,288
453,649,307
460,437,715
576,908,449
504,539,379
504,539,379576,908,449460,437,715453,649,307443,532,288237,398,253257,361,746260,104,118261,146,825262,038,107276,166,482278,087,539278,786,350159,117,490152,886,500146,933,095151,736,877179,547,918126,653,593125,042,274000000000000000000000000
       Property Plant Equipment 
11,484,534
12,156,769
14,848,478
21,199,547
22,068,539
22,664,515
22,479,729
22,586,646
22,660,617
23,594,007
24,244,586
25,110,769
25,403,026
25,415,048
25,252,312
25,947,984
24,355,840
17,622,606
17,435,520
18,164,021
18,077,707
17,668,105
17,469,223
17,327,250
17,474,781
17,759,937
45,619,923
45,907,245
20,295,174
20,214,965
19,836,072
19,800,749
19,711,630
19,428,352
19,410,220
18,856,620
18,655,421
18,590,378
18,377,379
323,773,107
319,946,950
319,280,959
322,420,501
318,211,931
318,211,931322,420,501319,280,959319,946,950323,773,10718,377,37918,590,37818,655,42118,856,62019,410,22019,428,35219,711,63019,800,74919,836,07220,214,96520,295,17445,907,24545,619,92317,759,93717,474,78117,327,25017,469,22317,668,10518,077,70718,164,02117,435,52017,622,60624,355,84025,947,98425,252,31225,415,04825,403,02625,110,76924,244,58623,594,00722,660,61722,586,64622,479,72922,664,51522,068,53921,199,54714,848,47812,156,76911,484,534
       Goodwill 
3,077,274
87,680
87,680
172,811
172,811
172,811
172,811
172,811
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000172,811172,811172,811172,811172,81187,68087,6803,077,274
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,207,344
42,835,821
40,206,918
68,748,983
62,883,743
67,627,224
104,246,370
108,863,998
107,520,744
102,612,315
103,913,169
119,632,007
91,966,747
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000091,966,747119,632,007103,913,169102,612,315107,520,744108,863,998104,246,37067,627,22462,883,74368,748,98340,206,91842,835,8219,207,344000000000000000
       Intangible Assets 
3,142,563
297,610
376,816
550,072
547,361
552,600
595,633
740,213
1,013,407
658,959
1,004,988
1,703,258
1,686,644
2,670,032
2,547,218
2,570,370
2,546,496
1,809,814
2,212,403
2,194,644
2,177,839
3,383,298
3,361,999
3,290,493
3,269,972
3,266,025
3,879,362
3,508,880
3,819,103
3,673,826
3,654,448
3,635,227
3,698,048
3,727,238
3,118,526
2,796,406
3,072,119
2,944,479
2,950,220
6,458,105
6,297,587
7,078,805
6,841,079
6,240,853
6,240,8536,841,0797,078,8056,297,5876,458,1052,950,2202,944,4793,072,1192,796,4063,118,5263,727,2383,698,0483,635,2273,654,4483,673,8263,819,1033,508,8803,879,3623,266,0253,269,9723,290,4933,361,9993,383,2982,177,8392,194,6442,212,4031,809,8142,546,4962,570,3702,547,2182,670,0321,686,6441,703,2581,004,988658,9591,013,407740,213595,633552,600547,361550,072376,816297,6103,142,563
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
125,042,274
0
1
0
0
0
-1
53,614
53,382
-144,081,547
39,666
49,021
27,042
20,988
18,812
21,574
18,531
86,720
30,056,458
27,983
27,98330,056,45886,72018,53121,57418,81220,98827,04249,02139,666-144,081,54753,38253,614-100010125,042,274000000000000000000000000
> Total Liabilities 
20,145,386
20,530,843
19,706,908
21,712,492
31,222,054
27,409,147
26,561,755
22,714,788
23,833,160
17,020,444
17,496,661
17,476,008
30,226,262
47,142,662
47,517,932
50,570,118
53,721,583
51,247,174
93,490,964
80,411,439
75,559,199
65,380,765
65,649,593
66,551,162
52,417,257
53,107,819
24,678,042
17,646,007
19,825,151
21,026,843
19,724,542
16,952,930
17,164,431
16,829,414
15,707,494
17,440,224
18,606,922
18,065,660
25,299,480
173,729,692
173,952,551
153,288,605
203,466,013
220,705,187
220,705,187203,466,013153,288,605173,952,551173,729,69225,299,48018,065,66018,606,92217,440,22415,707,49416,829,41417,164,43116,952,93019,724,54221,026,84319,825,15117,646,00724,678,04253,107,81952,417,25766,551,16265,649,59365,380,76575,559,19980,411,43993,490,96451,247,17453,721,58350,570,11847,517,93247,142,66230,226,26217,476,00817,496,66117,020,44423,833,16022,714,78826,561,75527,409,14731,222,05421,712,49219,706,90820,530,84320,145,386
   > Total Current Liabilities 
12,188,728
11,880,700
9,255,153
9,544,634
18,028,832
14,334,554
13,331,016
10,399,388
11,851,711
8,899,069
9,396,904
9,885,038
9,737,743
10,348,051
26,028,408
45,150,062
48,786,651
47,800,531
46,369,465
33,969,562
27,359,069
60,857,442
60,963,420
62,042,788
46,733,505
47,331,544
17,482,645
10,814,790
12,045,485
11,999,215
10,569,810
8,674,953
8,713,551
8,604,594
7,716,436
9,448,799
10,466,120
9,689,556
16,794,400
161,106,058
159,837,621
84,729,138
132,821,959
157,938,368
157,938,368132,821,95984,729,138159,837,621161,106,05816,794,4009,689,55610,466,1209,448,7997,716,4368,604,5948,713,5518,674,95310,569,81011,999,21512,045,48510,814,79017,482,64547,331,54446,733,50562,042,78860,963,42060,857,44227,359,06933,969,56246,369,46547,800,53148,786,65145,150,06226,028,40810,348,0519,737,7439,885,0389,396,9048,899,06911,851,71110,399,38813,331,01614,334,55418,028,8329,544,6349,255,15311,880,70012,188,728
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,040,866
38,262,675
38,981,175
30,871,417
22,397,964
15,724,396
5,538,489
33,246,971
6,089,703
30,124,055
31,188,018
9,910,505
3,446,401
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000003,446,4019,910,50531,188,01830,124,0556,089,70333,246,9715,538,48915,724,39622,397,96430,871,41738,981,17538,262,67537,040,866000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,040,866
38,262,675
38,981,175
30,871,417
22,397,964
15,724,396
5,538,489
33,246,971
6,089,703
30,124,055
31,188,018
9,910,505
3,446,401
3,832,341
4,415,542
3,941,444
2,621,100
2,231,274
2,012,210
1,671,427
2,161,636
2,213,400
2,584,063
9,066,973
134,263,397
139,345,872
66,318,358
103,145,040
129,360,289
129,360,289103,145,04066,318,358139,345,872134,263,3979,066,9732,584,0632,213,4002,161,6361,671,4272,012,2102,231,2742,621,1003,941,4444,415,5423,832,3413,446,4019,910,50531,188,01830,124,0556,089,70333,246,9715,538,48915,724,39622,397,96430,871,41738,981,17538,262,67537,040,866000000000000000
       Accounts payable 
1,411,618
1,451,248
449,050
601,008
776,088
457,787
448,542
341,733
519,039
574,736
501,527
653,572
563,044
792,282
365,204
520,463
579,991
541,847
504,329
489,296
594,213
389,549
547,891
707,679
598,427
640,057
622,545
535,877
1,333,279
818,062
782,713
808,222
919,931
627,159
639,654
652,594
648,571
826,615
854,924
3,808,672
7,361,043
3,860,012
3,550,370
1,333,066
1,333,0663,550,3703,860,0127,361,0433,808,672854,924826,615648,571652,594639,654627,159919,931808,222782,713818,0621,333,279535,877622,545640,057598,427707,679547,891389,549594,213489,296504,329541,847579,991520,463365,204792,282563,044653,572501,527574,736519,039341,733448,542457,787776,088601,008449,0501,451,2481,411,618
       Other Current Liabilities 
5,315,367
4,968,753
4,862,103
6,571,177
4,785,641
5,430,768
4,812,552
4,396,404
4,857,102
4,574,357
4,705,705
4,708,045
5,003,551
5,049,856
5,690,964
8,668,733
10,888,985
8,277,509
10,991,911
6,723,420
6,571,041
23,046,131
22,619,845
22,767,280
15,379,277
0
0
5,984,360
5,959,897
5,814,673
5,201,795
4,338,916
4,542,294
5,000,871
4,478,657
5,233,671
5,669,042
4,841,273
4,975,590
1
0
1
1
0
011014,975,5904,841,2735,669,0425,233,6714,478,6575,000,8714,542,2944,338,9165,201,7955,814,6735,959,8975,984,3600015,379,27722,767,28022,619,84523,046,1316,571,0416,723,42010,991,9118,277,50910,888,9858,668,7335,690,9645,049,8565,003,5514,708,0454,705,7054,574,3574,857,1024,396,4044,812,5525,430,7684,785,6416,571,1774,862,1034,968,7535,315,367
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,683,752
5,776,275
7,195,397
6,831,217
7,779,665
9,027,627
9,154,731
8,277,977
8,450,880
8,224,820
7,991,057
7,991,425
8,140,802
8,376,104
8,505,080
12,623,634
14,114,930
68,559,467
70,644,054
62,766,819
62,766,81970,644,05468,559,46714,114,93012,623,6348,505,0808,376,1048,140,8027,991,4257,991,0578,224,8208,450,8808,277,9779,154,7319,027,6277,779,6656,831,2177,195,3975,776,2755,683,752000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-37,040,866
-38,262,675
-38,981,175
-30,871,417
-22,397,964
-15,724,396
-5,538,489
-33,246,971
-6,089,703
-29,914,692
-31,010,350
-9,489,207
-3,029,733
529,118
490,334
0
349,690
371,639
374,607
378,380
319,494
281,288
148,450
164,620
474,562
0
0
0
19,637,004
19,637,004000474,562164,620148,450281,288319,494378,380374,607371,639349,6900490,334529,118-3,029,733-9,489,207-31,010,350-29,914,692-6,089,703-33,246,971-5,538,489-15,724,396-22,397,964-30,871,417-38,981,175-38,262,675-37,040,866000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
-1
-10011000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,323,129
2,323,129
2,323,129
2,323,129
2,323,129
2,323,129
2,323,129
1,276,171
0
0
0
0
274,300
603,900
478,000
478,000
478,000
448,000
478,000
0
0
0
0
0
0
0
0
0
0
0000000000478,000448,000478,000478,000478,000603,900274,30000001,276,1712,323,1292,323,1292,323,1292,323,1292,323,1292,323,1292,323,129000000000000000
> Total Stockholder Equity
63,025,663
56,723,168
56,757,062
56,254,594
55,898,879
55,370,265
60,066,080
62,329,623
62,786,538
67,624,477
67,579,226
69,225,163
76,515,093
83,697,465
83,052,700
80,404,977
79,579,457
73,990,606
75,142,273
77,860,648
81,137,483
152,301,758
154,099,622
150,510,886
144,428,677
146,006,779
249,171,148
246,342,741
251,022,733
264,350,631
505,266,213
505,394,898
504,040,710
505,473,473
506,524,091
507,938,605
509,844,781
511,625,734
515,506,969
426,521,105
421,356,723
475,577,517
479,188,863
368,691,478
368,691,478479,188,863475,577,517421,356,723426,521,105515,506,969511,625,734509,844,781507,938,605506,524,091505,473,473504,040,710505,394,898505,266,213264,350,631251,022,733246,342,741249,171,148146,006,779144,428,677150,510,886154,099,622152,301,75881,137,48377,860,64875,142,27373,990,60679,579,45780,404,97783,052,70083,697,46576,515,09369,225,16367,579,22667,624,47762,786,53862,329,62360,066,08055,370,26555,898,87956,254,59456,757,06256,723,16863,025,663
   Common Stock
59,448,049
59,448,049
60,972,982
67,436,315
67,436,315
68,036,565
73,889,947
77,389,947
77,389,947
80,389,947
40,202,224
40,286,574
40,395,324
40,433,974
40,436,474
40,437,474
40,441,724
40,441,724
41,319,771
42,314,464
43,384,778
53,941,097
53,941,097
53,941,097
53,941,097
53,991,097
120,829,164
120,829,164
120,829,164
120,829,174
199,287,883
199,287,884
199,287,884
199,287,884
199,287,884
199,287,884
199,287,884
199,287,941
199,287,941
0
0
0
0
0
00000199,287,941199,287,941199,287,884199,287,884199,287,884199,287,884199,287,884199,287,884199,287,883120,829,174120,829,164120,829,164120,829,16453,991,09753,941,09753,941,09753,941,09753,941,09743,384,77842,314,46441,319,77140,441,72440,441,72440,437,47440,436,47440,433,97440,395,32440,286,57440,202,22480,389,94777,389,94777,389,94773,889,94768,036,56567,436,31567,436,31560,972,98259,448,04959,448,049
   Retained Earnings 
1,091,452
1,070,961
1,130,620
1,320,930
1,366,942
0
1,441,300
1,478,682
1,503,267
1,521,757
1,492,454
1,043,172
467,375
201,952
189,811
182,265
-13,441,907
150,191
124,520
124,520
124,520
-31,397,083
-28,436,907
-33,283,698
-39,121,395
-37,560,506
-39,095,951
-41,771,364
-38,519,072
-34,780,515
-30,116,938
-30,114,077
-28,104,878
-26,060,765
-22,991,417
-21,114,746
-18,468,746
-15,246,259
-10,612,839
-8,085,486
-12,662,119
-30,057,629
-34,561,541
-133,309,950
-133,309,950-34,561,541-30,057,629-12,662,119-8,085,486-10,612,839-15,246,259-18,468,746-21,114,746-22,991,417-26,060,765-28,104,878-30,114,077-30,116,938-34,780,515-38,519,072-41,771,364-39,095,951-37,560,506-39,121,395-33,283,698-28,436,907-31,397,083124,520124,520124,520150,191-13,441,907182,265189,811201,952467,3751,043,1721,492,4541,521,7571,503,2671,478,6821,441,30001,366,9421,320,9301,130,6201,070,9611,091,452
   Capital Surplus 00000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000-41,271-41,271-41,271-41,271-41,271-41,271-41,271-41,271-41,271-41,271-41,271-41,271-42,347-2,147-2,147-2,147-2,147-2,147-2,147-2,147-2,147-2,147-2,147
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,280,548
2,984,548
291,080
-534,206
-845,770
-732,373
1,816,603
670,059
1,928,114
1,780,314
1,245,581
1,817,266
1,664,273
3,091,973
5,202,290
8,421,054
8,546,875
5,184,444
4,573,093
2,554,363
2,092,206
1,352,382
-88,041
-840,227
0
0
0
0
0
00000-840,227-88,0411,352,3822,092,2062,554,3634,573,0935,184,4448,546,8758,421,0545,202,2903,091,9731,664,2731,817,2661,245,5811,780,3141,928,114670,0591,816,603-732,373-845,770-534,206291,0802,984,5481,280,548000000000000000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue87,363,628
Cost of Revenue-99,027,109
Gross Profit-11,663,481-11,663,481
 
Operating Income (+$)
Gross Profit-11,663,481
Operating Expense-145,158,782
Operating Income-57,795,154-156,822,264
 
Operating Expense (+$)
Research Development14,999,891
Selling General Administrative18,553,622
Selling And Marketing Expenses0
Operating Expense145,158,78233,553,513
 
Net Interest Income (+$)
Interest Income4,488,199
Interest Expense-3,668,234
Other Finance Cost-4,208,454
Net Interest Income-3,388,489
 
Pretax Income (+$)
Operating Income-57,795,154
Net Interest Income-3,388,489
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-113,383,005-57,795,154
EBIT - interestExpense = -3,668,234
-118,269,721
-114,601,487
Interest Expense3,668,234
Earnings Before Interest and Taxes (EBIT)0-109,714,771
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-113,383,005
Tax Provision-1,947,066
Net Income From Continuing Ops-115,330,071-115,330,071
Net Income-118,269,721
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net03,388,489
 

Technical Analysis of En
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of En. The general trend of En is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine En's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aprogen Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 270.00 < 300.00 < 308.00.

The bearish price targets are: 192.00 > 168.00 > 156.00.

Tweet this
Aprogen Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aprogen Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aprogen Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aprogen Pharmaceuticals Inc. The current macd is 2.43797591.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the En price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for En. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the En price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Aprogen Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAprogen Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aprogen Pharmaceuticals Inc. The current adx is 33.43.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy En shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Aprogen Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aprogen Pharmaceuticals Inc. The current sar is 176.89.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Aprogen Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aprogen Pharmaceuticals Inc. The current rsi is 49.61. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Aprogen Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAprogen Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aprogen Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the En price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Aprogen Pharmaceuticals Inc Daily Stochastic Oscillator ChartAprogen Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aprogen Pharmaceuticals Inc. The current cci is 31.39.

Aprogen Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAprogen Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aprogen Pharmaceuticals Inc. The current cmo is -1.08923928.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aprogen Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAprogen Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aprogen Pharmaceuticals Inc. The current willr is -58.44155844.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that En is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Aprogen Pharmaceuticals Inc Daily Williams %R ChartAprogen Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aprogen Pharmaceuticals Inc.

Aprogen Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aprogen Pharmaceuticals Inc. The current atr is 17.80.

Aprogen Pharmaceuticals Inc Daily Average True Range (ATR) ChartAprogen Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aprogen Pharmaceuticals Inc. The current obv is 112,697,520.

Aprogen Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAprogen Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aprogen Pharmaceuticals Inc. The current mfi is 63.10.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Aprogen Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAprogen Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aprogen Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-02STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-17STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Aprogen Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aprogen Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.615
Ma 20Greater thanMa 50183.050
Ma 50Greater thanMa 100188.380
Ma 100Greater thanMa 200245.680
OpenGreater thanClose194.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of En with someone you think should read this too:
  • Are you bullish or bearish on En? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about En? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aprogen Pharmaceuticals Inc

I send you an email if I find something interesting about Aprogen Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aprogen Pharmaceuticals Inc.

Receive notifications about Aprogen Pharmaceuticals Inc in your mailbox!